A number of strategies have been investigated to improve therapeutic vascularization of ischemic and bioengineered tissues. In these studies, we genetically modified vascular smooth muscle cells (VSMC) to promote endothelial cell proliferation, migration, and formation of microvascular networks. VSMCs were virally transduced to produce vascular endothelial growth factor (VEGF), which acts as a chemoattractant and mitogen of endothelial cells (EC). VSMCs transduced with VEGF 165 cDNA produced significant levels of the protein (2-4 ng/10 5 cell/day). The proliferation of ECs increased after exposure to VEGF-transfected SMCs or their conditioned media. The chemotactic response of ECs to the VEGF-producing cells was explored in two in vitro systems, the modified Boyden chamber assay and a 2-D fence-style migration assay, and both demonstrated increased migration of ECs in response to VEGF-transfected cells. Furthermore, endothelial cells seeded on top of the VEGF-transfected SMCs formed capillary-like structures. These results suggest that VSMCs genetically modified to produce VEGF could be a potential delivery mechanism to enhance endothelial cell migration and subsequent capillary formation, which in turn could improve vascularization of ischemic or regenerating tissue. Furthermore, this system could potentially be used as an in vitro test bed for evaluation of novel angiogenic and anti-angiogenic compounds.
INTRODUCTION T
HE AIM OF TISSUE ENGINEERING is to replace damaged, injured, or missing tissues with biologically compatible substitutes. A major challenge limiting the success of tissue engineering is vascularization of three-dimensional engineered tissues. Vascularization is essential for supplying the cells with oxygen and nutrients and for removing metabolic byproducts. Insufficient vascularization has been proposed as the dominant cause for the unreliable survival of regenerated tissue. Vascularization of engineered tissue has generally been accomplished post-transplantation via ingrowth of capillaries from the surrounding tissue.
Ischemia, a tissue condition in which oxygen demand exceeds oxygen supply, results from a deficiency of the blood vessel supply, which leads to insufficient perfusion of oxygenated blood. The body responds to ischemic episodes in cardiac and peripheral tissue by developing new vessels to increase the blood supply, a process known as angiogenesis. Angiogenesis in the adult occurs by sprouting from existing vessels, a process that requires proliferation and migration of endothelial cells and remodeling of extracellular matrix. Alternatively, capillaries from undifferentiated endothelial cells can assemble in situ, a process known as vasculogenesis. Angiogenic factors have been used to reduce ischemia by enhancing collateral circulation to tissue. 1, 2 Both revascularization of ischemic tissue and "de novo" vascularization of bioengineered tissues have similar requirements, which fundamentally involve the proliferation and migration of endothelial cells and the development of a vascular network.
A strategy to promote vascularization is local delivery of growth factors that promote angiogenesis. Although several growth factors have been implicated in the angiogenesis process, vascular endothelial growth factor (VEGF) stands out because of its potent and specific mitogenic activity that is relatively restricted to endothelial cells. 3 VEGF-induced angiogenesis has been used for the treatment of ischemic peripheral vascular disease by promoting blood flow and expanding the vascular bed. 2 Like many growth factors, the relatively short biological half-life of VEGF leads to its rapid biodegradation, which is a major limitation in therapeutically delivering such a protein. 4 Furthermore, there have been reports that show that bolus injection of VEGF may cause hypotension. 5 Concerns surrounding the inability of endothelial cells in ischemic tissue to respond to the low levels of exogenously delivered VEGF prompted the use of more potent systems that could yield an effective angiogenic response. Sustained and localized delivery of VEGF is a potential approach to promote formation of new vascular networks. 6 Our goal in this study was to explore the potential of VSMCs transfected to produce VEGF to induce the growth, migration, and differentiation of endothelial cells using in vitro systems. Such genetically modified cells could be used as a local source of VEGF at a tissue site where enhanced vascularization was desired. This model may also be applied for analysis of potential angiogenenic and anti-angiogenic agents.
MATERIALS AND METHODS

Cell culture
Vascular smooth muscle cells (VSMC) were isolated from the thoracic aortae of adult Sprague-Dawley rats, as previously described, 7 and used between passages 2 and 8. Human umbilical vein endothelial cells (HUVEC) were obtained from ATCC and used between passages 2 and 6. All cells were maintained in high-glucose (1 g/L) Dulbecco's modified Eagle's medium (DMEM, Sigma, St. Louis, MO) that contained 10% fetal bovine serum (FBS, Clonetics, San Diego, CA), 2 mM L-glutamine, 1 U/mL penicillin, and 1 g/mL streptomycin (GPS, Sigma). Cell numbers were determined by Coulter counting (Multisizer 3, Beckman Coulter, Fullerton, CA).
Transfection experiments
Human VEGF and enhanced GFP cDNA were cloned into a retroviral expression vector (PLE-N1 provided by Dr. Michael Barry, Baylor College of Medicine). hVEGF cDNA was kindly provided by Dr. Shay Soker (Harvard Medical School). Retrovirus was produced by transient transfection of the amphotropic Phoenix packaging cell ELBJEIRAMI AND WEST line (provided by Dr. Gary Nolan, Stanford University) and pseudotyped with vesicular stomatitis virus G-glycoprotein. For transfection of VSMCs, the cells were plated at 7500 cell/cm 2 and supplemented with the viral supernatant at 1 mL/10 cm 2 . The expression cassette harbored a neomycin-resistance gene that enabled selection with G418 (CalBiochem, San Diego, CA). At 48 h after transfection, G418 was added at a final concentration of 0.5 g/mL. The medium was changed every 2 days for a 14 day selection period. Resistant cells at ϳ85% confluency were trypsinized and seeded for the designated experiments. Retroviral transduction with enhanced green fluorescence protein (eGFP) was used for mock transfections as a control.
Determination of VEGF levels released from transduced SMCs
Human VEGF protein expression was assessed by Western analysis. The heparin-binding ability of VEGF allows its capture following secretion using heparin-coated beads (Heparin sepharose CL-6B, Amersham Pharmacia, Piscataway, NJ). Heparin bead suspension (200 L) in phosphate-buffered saline (PBS, 140 mg/mL) was added to a 10 mL aliquot of conditioned medium and agitated slowly overnight at 4°C. The heparin-bound material was collected by low-speed centrifugation (ϳ1550xg), washed twice with PBS, and once in de-ionized water. Then, 60 L of SDS-PAGE sample buffer (20 mM Tris-HCl at pH 6.8 with 2% SDS, 100 mM ␤-mercaptoethanol, 20% glycerol, and 0.02% bromophenol blue) was added to the washed beads, boiled for 2 min, and analyzed on a 15% SDS-PAGE gel. After transferring to a nitrocellulose membrane, the protein was blotted with a commercially available polyclonal antibody against rhVEGF (Oncogene Research, San Diego, CA), followed by detection using an HRP-linked anti-rabbit IgG antibody (Bio-Rad, Hercules, CA) and ECL chemiluminescence system (Amersham).
VEGF protein concentration was quantified in the conditioned medium collected from transfected cells using an enzyme-linked immunosorbent assay (ELISA) following the manufacturer's instructions (R&D Systems, Minneapolis, MN).
Proliferation using conditioned media
Proliferation of HUVECs in response to VEGF-transfected SMCs was examined through exposure of HUVECs to SMCs' conditioned media. The transfected SMCs were maintained on complete endothelial growth media (cEGM, Clonetics). The conditioned media were collected every 2 days, and the number of SMCs was determined using a Coulter counter to normalize for cell number. Endothelial cells were seeded into 6-well multiwell plates (Becton Dickinson Labware, Franklin Lakes, NJ) at 7500 cell/cm 2 and then exposed to the SMC con-ditioned media. Fresh conditioned media were added to HUVECs every 2-3 days, at which time cells were trypsinized and counted using a Coulter Counter as described above. A VEGF-neutralizing antibody (R&D Systems) was added at 0.4 g/mL in some wells as a control. Approximately 0.01-0.03 g/mL of the antibody will neutralize 50% of the bioactivity due to 10 ng/mL of rhVEGF; 0.08 g/mL of this antibody is sufficient for achieving complete neutralization of the protein according to the manufacturer.
Proliferation using co-culture assay
The proliferative effect of VEGF-transfected SMCs on HUVECs was tested in a co-culture model. VEGF-or mock-transfected SMCs were seeded into 6-well culture insert companion plates (Becton Deckinson Labware) at 30,000 cell/cm 2 and allowed to adhere overnight. HUVECs were seeded onto 0.4 m pore size polycarbonate-membrane inserts (these do not allow cell migration, but do permit diffusion of soluble factors) at 15,000 cell/cm 2 and were placed above the SMCs already present in the 6-well plates. Before the introduction of endothelial cells to the inserts, the culture medium in the SMC seeded wells was exchanged for the endothelial cell media. After culturing for 72 h, the cells on the inserts were trypsinized to determine HUVECs cell number using Coulter counting as described above. A VEGF-neutralizing antibody (1.25 g/mL; R&D Systems) was added to some wells as a control. The amount of VEGF produced in VEGF-SMC wells was determined using an ELISA as described above.
Cell migration assays
Transwell migration assay. HUVECs were seeded in transwell cell culture inserts (8 m pore size; permissible of cell migration) at 64,000 cell/cm 2 and placed in 6-well insert companion plates previously seeded with the transfected SMCs at 25,000 cell/cm 2 . A VEGF-neutralizing antibody (R&D Systems) was used at 0.55 g/mL final concentration in some wells as a control. At 28 h post-seeding, the inserts were washed with PBS and trypsinized to determine the number of HUVECs on top of and beneath the transwells using Coulter counting. Migration was then evaluated as
Migration index ϭ
Two-dimensional migration assay. A disc-shaped mold made of stainless steel was designed such that two chambers allow seeding of ECs and SMCs independently into separate wells (Fig. 1) . The height of the mold was 12 mm while the distance between the centers of both cham-# cells below insert ᎏᎏᎏᎏᎏ # cells below insert ϩ # cells above insert ENDOTHELIAL CELLS COCULTURED WITH VEGF-PRODUCING SMCs bers was 17 mm. Transfected SMCs and endothelial cells were seeded independently into each chamber (90,000 cell/cm 2 ) and allowed to adhere for 8 h. The molds were removed under sterile conditions after marking the boundaries of seeded areas, and cEGM was added to the whole well. The media were supplemented with mitomycin C (0.5 g/mL; Calbiochem) to block cell growth so that solely chemotactic effects of VEGF could be assessed. The migration of ECs toward the SMCs was monitored using phase contrast microscopy.
Seeding of endothelial cells on smooth muscle cell layers
VSMCs were seeded into 6-well plates at 25,000 cell/cm 2 and allowed to adhere overnight. HUVECs were then seeded onto the VSMCs at 15,000/cm 2 and allowed to adhere. At various time points, the cells were immunostained for CD31/PECAM-1. The cells (n ϭ 3 well/group) were washed with phosphate-buffered saline, fixed with 10% formalin for 10 min, and treated with 0.3% H 2 O 2 for 10 min. The wells were next incubated in blocking serum (0.3% FBS) for 2 h, followed by the addition of mouse monoclonal anti-CD31 antibody (Sigma) at 1:150 dilution in blocking serum overnight. The wells were washed with PBS and incubated with an HRP-conjugated rabbit anti-mouse IgG (DakoCytomation, Carpinteria, CA) for 50 min. AEC substrate system (DakoCytomation) was used to detect secondary antibody. Wells stained in the absence of primary antibody were used as negative controls. Samples were analyzed by light microscopy (Zeiss Axiovert 135). 
Statistical analysis
Data sets were compared using two-tailed, unpaired t tests. P values Ͻ0.05 were considered significant.
RESULTS
VEGF-transduction of vascular smooth muscle cells
Our goal in this study was to implement ex vivo gene therapy as a tool to potentially enhance vascularization of ischemic and bioengineered tissue. Rat aortic smooth muscle cells were retrovially transduced with VEGF 165 full cDNA. The transfection included a neo-resistance expression vector. G418 treatment, used as a selection step, rendered visible resistant colonies after 7-10 days. Western analysis showed increased levels of VEGF protein in the conditioned media of VEGF-transduced SMCs (Fig.  2 ) as compared to GFP-transfected control cells. Quantitative analysis using ELISA detected VEGF expression in the VEGF-transduced cells at 2-4 ng/10 5 cell/day.
Evaluation of the mitogenic effect of VEGFtransfected SMCs on endothelial cells
The ability of VEGF-transfected SMCs to induce a mitogenic effect on ECs was evaluated by two methods. First, the conditioned media of transfected SMCs were added to ECs seeded alone. HUVEC exposure to conditioned media of VEGF-transfected SMCs for 72 h resulted in increased cell number as compared to HUVECs that received mock-conditioned media from GFP-transfected cells (Fig. 3) . By day 5 in culture, HUVEC growth was greater in wells exposed to the conditioned media of VEGF-transfected SMCs as compared to cells exposed to the mock-conditioned media. When the HUVECs were exposed to conditioned media of VEGF-transfected SMCs in the presence of a neutralizing antibody, the ELBJEIRAMI AND WEST growth of HUVECs was reduced to that seen in control wells. Second, the mitogenic response of ECs was evaluated in a co-culture model. When HUVECs were cocultured with VEGF-transfected SMCs for 72 h, the endothelial cells exhibited a progressive increase in number. When the HUVECs were co-cultured with VEGF-transfected SMCs in the presence of a neutralizing antibody, the growth rates were similar to those observed using GFP-transfected cells (Fig. 4) . The VEGF levels produced by VEGF-transfected SMCs in the co-culture study were determined at 72 h using ELISA and found to be 8 ng/mL.
Evaluation of the chemotactic effect VEGFtransfected SMCs exert on endothelial cells
The migratory response of ECs to the transfected SMCs was first determined using a modified Boyden chamber migration assay. The number of ECs that had migrated through the insert at 28 h nearly doubled following exposure to VEGF-transfected SMCs (Fig. 5) . The addition of a neutralizing antibody inhibited migration of ECs to levels seen in control wells containing GFP-transfected SMCs.
In a 2-D model where migration is easily visualized, ECs and transfected SMCs were seeded in wells separated by fences that were removed following cell attachment to allow interaction of secreted factors. Mitomycin C was supplemented into the cell media to impede proliferation by blocking the cell cycle at the G 2 phase, thus allowing one to assess VEGF's effects on migration. At 96 h post-seeding, the extent of EC migration in wells containing VEGF-expressing SMCs was greater than that 
FIG. 3.
Growth of endothelial cells exposed to conditioned media of transfected SMCs. HUVECs proliferation was enhanced following exposure to conditioned media of VEGFtransfected SMCs in the absence of a neutralizing antibody (Ϫ), but was reduced following the antibody addition (ϩ). Line indicates original seeding density. Results are expressed as mean Ϯ SEM. *p ϭ 0.03, #p ϭ 0.004 compared to mockSMCs (n ϭ 3 per group). observed in control wells seeded with GFP-SMCs ( Fig.  6A and B) . The EC migration in VEGF-seeded wells was decreased to that seen in control wells after addition of a neutralizing antibody ( Fig. 6C and D) .
Formation of capillary-like networks by endothelial cells
Immunohistochemical staining for CD31/PECAM-1, an endothelial cell marker, demonstrated a dramatic increase in the number of interconnecting capillary-like networks in wells where ECs were seeded onto VEGFtransfected SMCs (Fig. 7) . By day 3, endothelial cells seeded onto VEGF-transfected SMCs became slightly elongated as compared to HUVECs that were seeded onto GFP-SMCs (Fig. 7B) . The addition of a VEGF-neutralizing antibody to wells harboring VEGF-transfected SMCs abolished this change in morphology (Fig. 7C) . Furthermore, by day 12, the appearance of a network is more evident in wells where ECs and VEGF-transfected SMCs were seeded ( Fig. 7D and E) . In contrast, control wells of GFP-transfected cells failed to form capillarylike structures (Fig. 7F) . The addition of a neutralizing antibody to the VEGF-transfected SMCs reduced the large capillary structures to small sprouts (Fig. 7G) . ELISA analysis determined the VEGF levels to be 8 ng/mL in wells harboring the VEGF-transfected SMCs.
DISCUSSION
A potentially promising strategy for improving vascularization of ischemic or engineered tissue is to stimulate endogenous angiogenesis. The generation of perfused vessels requires recruitment and proliferation of endothelial cells as well as the subsequent recruitment of mural cells, such as the pericytes and smooth muscle cells (SMCs). The nascent vessels are stabilized by generation ENDOTHELIAL CELLS COCULTURED WITH VEGF-PRODUCING SMCs of an extracellular matrix, which serves as a reservoir for various growth factors and proenzymes involved in vessel development. Recent evidence suggests that angioblast-like cell precursors derived from the bone marrow circulate in the adult vasculature and contribute to physiological and pathological neovascularization in the adult. 8, 9 It has been shown that these circulating stem cell precursors are able to invade tissues and differentiate following ischemic damage. 10 These findings are important because they provide evidence that a reservoir of cells is readily available in vivo for vessel formation.
Enhancing angiogenesis through delivery of growth factors is one approach to establishing a vascular network. The identification and characterization of various angiogenic factors now permit the problem of neovascularization to be addresses. Because of the short half-life of growth factors, continuous local delivery over an extended period is preferable via controlled release from a polymer matrix or through gene therapy. Genetic engineering of cells promises to be an effective delivery method due to the sustained release of overexpressed growth factors as compared to the burst release by polymeric matrices. 11, 12 Ex vivo transfection of different cell types with various growth factors to stimulate angiogenesis has been extensively studied. [13] [14] [15] [16] [17] Grafting of genetically modified cells that overexpress angiogenic factors has been shown to elicit the angiogenic process. 13, 18, 19 VEGF-expressing keratinocytes used in dermal substitutes have increased vascularization and thus improved composite skin grafts. 19 However, the angiogenic response might differ according to the growth factor, since each growth factor has a unique mechanism for expressing its activity. 17 Vascular endothelial growth factor is one of the most specific and potent angiogenic growth factors currently 
FIG. 5.
Effect of VEGF production by SMCs on EC migration was examined using a modified Boyden chamber apparatus. ECs exposed to VEGF-transfected cells exhibited increased migration (Ϫ) that was reduced following addition of a neutralizing antibody (ϩ) to levels seen in control wells. Results are expressed as mean Ϯ SEM. *p ϭ 0.001 compared to mockSMCs (Ϫ) (n ϭ 4).
known. The VEGF family comprises six members whose biological effects are mediated via cell-surface-expressed receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR), and VEGFR-3 (Flt-4). 20 The major differences between the VEGF isoforms include their ability to bind heparin and their solubility. 21 Although the two most abundant isoforms, VEGF 165 and VEGF 121 , have similar activities, the latter is 50-to 100-fold less potent than VEGF 165 , as determined in an EC proliferation assay. 22 VEGF signaling has been shown to play an important role in nascent vascular development. 23 VEGF initiates vessel formation, setting a chain of molecular and cellular events in motion that ultimately lead to vessel maturation. 24, 25 Evidence that VEGF is a specific EC growth factor has suggested its potential in therapeutic angiogenesis. 18, 26 For example, injection of VEGF 165 protein has enhanced the revascularization of an ischemic hind limb of a rabbit. 2 Furthermore, improved therapeutic angiogenesis using gene therapy has been reported to show better prospects than using the recombinant protein. 1, 2, 27, 28 Recently, comparison studies addressing stimulation of angiogenesis by gene transfer of VEGF and other growth factors have been reported. 14,17,29 Kondoh et al. 17 delivered VEGF or basic fibroblast growth factor (bFGF) by using an ex vivo gene delivery system and compared the characteristics of collateral development promoted by these factors in a rabbit model of chronic hind limb ischemia. Although their findings suggest that bFGF-induced collateral development exceeds VEGF-induced collateral development in the induction of arteriogenesis, there re-ELBJEIRAMI AND WEST mains a major concern about the high smooth muscle cell (SMC) vessel density associated with bFGF-mediated vessel formation. Indeed, bFGF does not only promote the proliferation of endothelial cells, but also induces the development of the medial layer. 30 In the study described here, the mitogenic and chemotactic effects of VEGF-transfected SMCs on endothelial cells were evaluated in vitro. The mitogenic effect of VEGF production on ECs was first evaluated by indirect exposure to conditioned media of the transfected cells. Endothelial cells exhibited a significant increase in cell number following their exposure to conditioned media of VEGF-transfected SMCs. The mitogenic effect VEGFSMCs exerted on ECs was also demonstrated using a coculture model where ECs were in proximity of transfected SMCs. These studies demonstrated that SMCs genetically engineered to overproduce VEGF are capable of stimulating EC proliferation. Djurovic et al. 31 have recently examined the effects of plasmids encoding VEGF 121 -cDNA and VEGF 165 -cDNA on proliferation of aortic and coronary endothelial cells and reported results comparable to our study. Moreover, they found a difference in proliferative response between the isoforms with pVEGF 165 yielding a higher stimulatory effect. Endothelial cell origin was another factor associated with the different observed proliferation rate between the aortic and coronary ECs. Our results show a higher proliferative response (ϳ40% difference to control, as compared to ϳ10% reported by Djurovic et al.) that could be due to higher levels of VEGF produced by the retrovirally transduced SMCs in our study as compared to lipotransfected cells in the Djurovic study. Also, different endothelial cell origins were used in the two studies; thus, dissimilar proliferative response would be expected.
ENDOTHELIAL CELLS COCULTURED WITH VEGF-PRODUCING SMCs
A second issue we wanted to explore is the ability of VEGF-expressing SMCs to promote migration of ECs. In our model, the chemotactic response of ECs to the transfected SMCs has been evaluated using two assays. A modified Boyden chamber migration assay was first selected because the chamber design permits easy quantitation of population migration data by allowing independent seeding of two cell types to study the effect of VEGF production in the lower chamber on EC migration through a membrane. Substantially more ECs migrated by 28 h following their co-culture with VEGF-transfected SMCs as compared to control cells. Moreover, the chemotactic response of ECs to VEGF-transfected SMCs was also explored in 2-D migration assays where ECs and SMCs were first seeded independently and then cultured in tandem using a fence-style assay. ECs significantly migrated toward the SMCs, suggesting that ECs were capable of invading a surface upon their exposure to angiogenic VEGF effects. In this study, addition of mitomycin C confirmed that increased endothelial cell number observed outside the initial marked boundary was due to cell migration rather than proliferation.
Finally, we wanted to demonstrate the potential of SMCs to induce capillary formation. The ability of endothelial cells to form capillaries was investigated by their culture onto a surface previously seeded with VEGF-transfected SMCs. The ECs responded in the first few days by elongating and stretching and later (day 12) by forming an interconnecting network that is clearly characteristic of capillaries. PECAM-1 staining was observed in the capillaries formed on the VEGF-SMC surface. PECAM-1, which is a cell adhesion molecule located at EC-EC junctions, is indicative of tube formation. 32 This model has the advantage of encompassing EC-SMC interactions, which are critical for providing stabilization to nascent vessels as both cell types are the main sources to factors critical to vessel growth, expansion, remodeling, and regression. 33 Data on the role of SMCs in providing stabilization signals to sprouting ECs have been reported. 34, 35 The angiogenic effect of VEGF-SMCs on the ECs suggests the former can be used to introduce a microvascular network in ischemic and engineered tissue.
Our model in this study consists of two components, VEGF-producing VSMCs and endothelial cells, which may potentially be an in vitro assay to measure endothelial tube formation. Several angiogenesis models have been developed in order to investigate the mechanisms of angiogenesis and to screen angiogenesis-modulating agents. 36, 37 The in vitro models are 3-D gel assays that are obtained by the culture of endothelial cells in gels made of various extracellular matrix compounds, such type I collagen, fibrin, fibronectin, or basement membrane extracts. 3 One major limitation to these models is the inability to study the interactions with different types of cells and with a complex extracellular matrix. Furthermore, the use of animal endothelial cells in these models entails a variability of cellular responses. 39 In this study, we used an in vitro model that allows human en-dothelial cells to have interactions with smooth muscle cells and the extracellular matrix they have produced. Indeed, by 12 days post-seeding, endothelial cells seeded on top of the VEGF-transfected SMCs formed capillarylike structures. This culture period time contrasts to the in vitro models where endothelial cells form capillary tubes within hours and thus may not demonstrate physiological behavior. 40, 41 Moreover, the formed capillaries persisted in culture up to 30 days (data not shown), thus making it possible to test angiogenic and anti-angiogenic factors over short-and long-term periods. Hudon et al. 39 have created an in vitro model to analyze the influence of drugs on angiogenesis. Their model is comprised of co-cultured dermal fibroblasts and umbilical vein endothelial cells in a collagen sponge biomaterial. This group reported results comparable to our study showing capillary formation by addition of angiogenic factors. However, our simple model has the advantage of co-culturing endothelial cells with their in vivo neighbor, smooth muscle cells. Thus, physiologically more relevant data could be obtained using our model to analyze the regulation of capillary tube formation and may be useful for screening possible angiogenenic and anti-angiogenic compounds.
In conclusion, genetic modification of VSMCs to produce VEGF is effective at enhancing endothelial cell migration and subsequent capillary formation. VEGF-producing VSMCs could be a potential delivery mechanism to improve vascularization of ischemic or regenerating tissue. Furthermore, this system could potentially be used as an in vitro test bed for evaluation of novel angiogenic and anti-angiogenic compounds.
